



# Respiratory Formulary and Pathways

For Adult Patients



**Northern Lincolnshire  
Area Prescribing Committee**



# Contents

LAMAs	1 - 5
LAMA / LABAs	6 - 8
ICS	9 - 10
ICS / LABAs	11 - 16
Drugs not for new initiation	17
Adult COPD Pathway	18
Adult Asthma Pathway	19

# LAMA - Eklira<sup>®</sup> Genuair<sup>®</sup> (Acclidinium)

- Maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD
- Recommended dose is one inhalation of 322 micrograms twice daily

## Features:

- Colour control window indicating dose ready (green) and delivered (red)
- Dose counter
- Audible click on dose delivery

## Technique:

- Inhale **STRONGLY** and **DEEPLY**



# LAMA - Incruse<sup>®</sup> Ellipta<sup>®</sup> (Umeclidinium)

- Maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD
- Recommended dose is one inhalation of umeclidinium bromide once daily

## Features:

- Dose counter
- Simple one-step priming procedure
- Not possible to accidentally take extra medicine or a double dose in one inhalation if the inhaler cover is opened and closed without inhaling the medicinal product



## Technique:

- One long, steady, deep breath

# LAMA – Seebri<sup>®</sup> Breezhaler<sup>®</sup> (Glycopyrronium)

- Maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD
- Recommended dosage is the inhalation of the contents of one capsule once daily using the Seebri Breezhaler device

## Features:

- Capsule makes whirring noise with sufficient inhalation rate
- Separate capsules give clear indication of number of doses remaining

## Technique:

- Breathe in rapidly but steadily, as deeply as you can



# LAMA - Spiriva® Handihaler® (Tiotropium)

- Maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD
- Recommended dosage is the inhalation of the contents of one capsule once daily with the HandiHaler device, at the same time of day



## Features:

- Capsule rattles with sufficient inhalation rate
- Separate capsules give clear indication of number of doses remaining

## Technique:

- Breathe in slowly and deeply but at a rate sufficient to hear or feel the capsule vibrate

# LAMA - Spiriva<sup>®</sup> Respimat<sup>®</sup> (Tiotropium)

- Maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD
- Add-on maintenance bronchodilator treatment in adult patients with asthma who are currently treated with the maintenance combination of inhaled corticosteroids ( $\geq 800$  micrograms budesonide/day or equivalent) and long-acting  $\beta_2$  agonists and who experienced one or more severe exacerbations in the previous year.
- The recommended dose for adults is 5 micrograms given as two puffs from the Respimat inhaler once daily, at the same time of the day



## Features:

- Dose indicator
- Soft mist for patients with limited inspiratory effort

## Technique:

- Slow, deep breath



# LAMA/LABA – Anoro<sup>®</sup> Ellipta<sup>®</sup> (Umeclidinium / Vilanterol)

- Maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD
- The recommended dose is one inhalation of ANORO 55/22 micrograms once daily, at the same time of day

## Features:

- Dose counter
- Simple one-step priming procedure
- Not possible to accidentally take extra medicine or a double dose in one inhalation if the inhaler cover is opened and closed without inhaling the medicinal product

## Technique:

- One long, steady, deep breath



# LAMALABA – Duaklir® (Acidinium / Formoterol)

- Maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD
- Recommended dose is one inhalation of Duaklir Genuair 340/12 micrograms twice daily

## Features:

- Colour control window indicating dose ready (green) and delivered (red)
- Dose counter
- Audible click on dose delivery

## Technique:

- Inhale **STRONGLY** and **DEEPLY**



# LAMA/LABA – Ultibro<sup>®</sup> (Glycopyrronium / Indacaterol)


- Maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD
- Recommended dosage is the inhalation of the contents of one capsule once daily using the Ultibro Breezhaler device

## Features:

- Capsule makes whirring noise with sufficient inhalation rate
- Separate capsules give clear indication of number of doses remaining

## Technique:

- Breathe in rapidly but steadily, as deeply as you can



# Asthma Step 2 inhaled corticosteroids

**Clenil® Modulite®** (Beclometasone 50-200 micrograms MDI) **2P BD**

**Qvar® Easi-Breathe®** (Beclometasone 50-100 micrograms Breath Actuated MDI) **2P BD**  
(note dose of Qvar must be halved with respect to Clenil due to finer particle size)

**Pulmicort® Turbohaler®** (Budesonide 100-400 micrograms DPI) **1-2P BD**

## Technique:

- pMDI inhalation rate should be  $<60\text{L}\cdot\text{min}^{-1}$
- Pulmicort: Breathe in forcefully and deeply



# ICS/LABA –DuoResp® Spiromax® (budesonide/formoterol)

- Indicated for the regular treatment of asthma in adults, where use of a combination (ICS and LABA) is appropriate:
  - Maintenance dose 1-2 inhalations twice daily (160/4.5 micrograms delivered dose)
  - Maintenance and reliever therapy up to 8 doses in 24 hours (160/4.5 micrograms delivered dose)
  - 320/9 micrograms delivered dose only licensed for maintenance therapy 1-2 inhalations twice daily
- Symptomatic treatment of adults with severe COPD (FEV<sub>1</sub> < 50% predicted) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators:
  - Dose 2 inhalations twice daily (160/4.5 micrograms)
  - 1 inhalation twice daily (320/9 micrograms)



# ICS/LABA –DuoResp® Spiromax® (budesonide/formoterol)

## Features:

- Simple one-step priming procedure
- Dose counter
- Audible click confirming priming of device

## Technique:

- Breathe in forcefully and deeply



# ICS/LABA –Fostair<sup>®</sup> MDI (beclometasone extrafine/formoterol)

- Indicated for the regular treatment of asthma in adults, where use of a combination (ICS and LABA) is appropriate:
  - Maintenance dose 1-2 inhalations (100/6 micrograms) twice daily
  - Maintenance and reliever therapy up to 8 doses in 24 hours
- Symptomatic treatment of adults with severe COPD (FEV<sub>1</sub> < 50% predicted) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators:
  - 2 inhalations twice daily



## Technique:

- Breathe in slowly and deeply
- pMDI inhalation rate should be <60L.min<sup>-1</sup>

# ICS/LABA –Fostair® Nexthaler® (beclometasone extrafine/formoterol)

- Indicated for the regular treatment of asthma in adults, where use of a combination (ICS and LABA) is appropriate:
  - Maintenance dose 1-2 inhalations (100/6 micrograms) twice daily



## Features:

- Simple one-step priming procedure
- Dose counter
- If no dose is inhaled after priming, the counter will not count down, and the dose will be moved back to the powder reservoir within the inhaler
- Audible click on dose delivery

## Technique:

- Breathe in quickly and deeply



# ICS/LABA –Relvar® Ellipta® (fluticasone furoate/vilanterol)

- Indicated for the regular treatment of asthma in adults and adolescents over 12 years, where use of a combination (ICS and LABA) is appropriate:
  - 92/22 micrograms 1 inhalation daily
  - 184/22 micrograms 1 inhalation daily
- Symptomatic treatment of adults with COPD with an  $FEV_1 < 70\%$  of predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy:
  - Dose 1 inhalation daily 92/22 micrograms strength ONLY for COPD



# ICS/LABA –Relvar® Ellipta® (fluticasone furoate/vilanterol)

## Features:

- Dose counter
- Simple one-step priming procedure
- Not possible to accidentally take extra medicine or a double dose in one inhalation if the inhaler cover is opened and closed without inhaling the medicinal product

## Technique:

- One long, steady, deep breath



# List of drugs that may be continued in patients stabilised on current therapy, but are **not for new initiation**

- Salbutamol 200 micrograms DPI
- Budesonide: MDI, Nebules
- Symbicort® Turbohaler® (budesonide/formoterol) 200/6 micrograms and 400/12 micrograms
- Seretide® Evohaler® and Accuhaler® (fluticasone/salmeterol)\*
- Flutiform (fluticasone/formoterol)\*

**Link to Northern Lincolnshire Area Prescribing Committee website:**

<http://www.northernlincolnshireapc.nhs.uk/formularydocuments/formulary/chapter-3/>

\*see full formulary

# COPD PATHWAY

FEV<sub>1</sub> >50% AND exacerbations <2 per annum

MRC 1 or 2  
Or CAT score <10

SABA or SAMA

MRC 3,4,5  
Or CAT score >10  
SABA or SAMA

LABA or LAMA

LABA + LAMA

FEV<sub>1</sub> ≤50% OR exacerbations >2 per annum

MRC 1 or 2  
Or CAT score <10  
LABA+LAMA

ICS+LABA or LAMA

ICS+LABA+LAMA


MRC 3,4,5  
Or CAT score >10  
ICS+LABA OR LAMA


ICS+LABA+LAMA

+/- Mucolytic

+/- Theophylline – Specialist Only

# ASTHMA PATHWAY (ADULTS)





This production of this booklet is kindly sponsored by: Teva UK Limited,  
Pfizer UK Ltd, Boehringer Ingelheim Limited & AstraZeneca UK Limited.  
Project Co-ordinator: Kieron Jones

Incruse®, Relvar® Anoro® and Ellipta® are registered trademarks of the GSK group of companies.  
©2014 GSK group of companies. All rights reserved.